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were satisﬁed with their health coverage (3.78 1.89).
Respondents in this study had low physical (PC) (47.23
± 9.69) and mental (MC) (47.11 ± 11.33) composite
scores on the SF-12 scale. There was a signiﬁcant corre-
lation between involvement in activities to improve health
and patient satisfaction scores. CONCLUSIONS: Con-
sumers were highly motivated to improve their health.
Health involvement could be used as a predictor of
humanistic outcomes in future studies.
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COSTS IN A MOTHER-CHILD TEACHING
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OBJECTIVE: To identify predictive factors of inpatient
drug costs in a 500-bed mother-child teaching hospi-
tal. METHODS: All hospitalisations in 2000/2001 and
2001/2002 were evaluated. Categorical variables in-
cluded were major category of diagnosis (MCD) (n =
25), severity index (n = 4), risk index (n = 4) and patient
care units (n = 41). Continuous variables included were
patient weight (kg), level of intensity of resources utilised
(LIRU) and total inpatient drug costs/patient-year. Out-
liers were excluded: inpatient drug costs/patient-year
greater than 5000 $CDN, LIRU > 50 and MCD with less
than 10 patients per ﬁscal year. MCD were analysed 
as serial dichomotical variables. Data were extracted
from the admission and the pharmacy software system.
RESULTS: Analysis were based on a cohort of 8479
patients in 2000/2001 and 7355 patients in 2001/2002.
Cost was divided by patient’s body weight and log-
transformed. A stepwise block multiple regression was
processed in two blocks: a ﬁrst block included LIRU,
severity index and risk index and a second block added
relevant MCD. Cumulative R2 were respectively 29.3 and
33.5 for both ﬁscal year. The standardised weight of the
variables included for both years were similar. Individual
R2 were 15.7 and 19.4 for LIRU, 4.7 and 3.3 for sever-
ity index, 0.1 and 0.2 for risk index and 8.9 and 10.6 for
a selection of relevant MCD. A third of total inpatient
drug costs/patient-year can be explained by level of inten-
sity of resources utilised, some major category of diag-
nosis, severity index and risk index. CONCLUSIONS:
There are limited information published on predictive
factors of inpatient drug costs/patient-year in hospitals.
Further analyses are required to build a useful and
stronger model for planning and benchmarking drugs
costs in hospitals.
PHP30
RATES OF CONTINUATION OF NON
FORMULARY MEDICATIONS FOR CHRONIC
DISEASE SUFFERERS IN MULTI-TIERED
PHARMACY BENEFIT PLANS
Nair KV1,Valuck RJ1,Allen RR2
1University of Colorado Health Sciences Center, Denver, CO,
USA; 2Peak Statistical Services, Evergreen, CO, USA
OBJECTIVE: Evaluate the impact of 3-tier pharmacy
beneﬁt structures on medication switching patterns.
METHODS: The study design was a “pre”-test/”post”-
test quasi-experimental design with comparison groups
using chronic disease sufferers from a health plan in the
Western US. Individuals with 2 prescriptions for a non
formulary medication (n = 1729) were classiﬁed by their
pharmacy beneﬁt group as: a) 2-tier moving to a 3-tier
structure, (“converting” group); b) 2-tier staying in a 2-
tier structure; and c) 3-tier staying in a 3-tier structure.
The latter two were “comparison” groups. Two time
periods were studies: the “pre” period before and the
“post” period, after a change in pharmacy beneﬁt struc-
ture. Cox regressions, adjusting for age, gender, chronic
disease scores and pharmacy plan structure, assessed dif-
ferences in the continuation rates of non formulary med-
ications across all groups. RESULTS: Over 60% switched
to formulary alternatives when faced with increased co-
payments, of which 43.3% switched to a brand alter-
native (p < 0.001). Less than 10% discontinued their
medication. Cumulative continuation rate was higher 
for the converting group: 30.1% (95% CI 27.6%–
34.1%) and similar for members in the two-tier compar-
ison group: 26% (95% CI 21.2%–32.6%). Three-tier
comparison group members were half as likely to con-
tinue their non formulary medications during the post
period: 17.1% (95% CI 14.3%–20.4%). CONCLU-
SIONS: Individuals confronted with increased co-
payments due to the implementation of a three-tier plan
often switched their medications to formulary alterna-
tives. While this ﬁnding supports the general purpose of
three-tier structures, of concern is the potential impact on
individuals who discontinued their medications due to
these changes.
HEALTHCARE POLICY—Healthcare Expenditure
Studies (Including Productivity)
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HIGH RATE OF OUT-OF-POCKET PAYMENTS IN
HEALTH CARE SYSTEMS
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OBJECTIVE: Among OECD countries Korea has the
highest rate of out-of-pocket payments (OOP) in the
health care system. This has been pointed out and sug-
gested that it should be much lower. This study investi-
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gates the rate of OOP in Korea. METHODS: Data from
World Health Report 2002 are used to analyze the rela-
tion between per capita total health care expenditure
(THE) of GDP and rates of OOP or rates of prepaid (i.e.
tax, premium, etc). To explain why the rate of OOP is
high in Korea, we compare price elasticity in demand for
medical services between countries from previous studies.
To argue that the OOP rate is not so serious currently and
in the future, we show the trend of OOP rates in Korea
for three decades. RESULTS: By comparing the relation
between per capita THE of GDP and rates of OOP or
rates of prepaid, we found the fact that the amount of
THE of GDP or THE of GDP per capita would be same
regardless of either high or low OOP rates, or high rates
of OOP might spend less THE because it can prevent
“moral hazard” in using medical services. This fact is
support by the higher price elasticity in demand for
medical services in Korea. In addition, we found that
OOP rates came down from 85% (1970) to 41% (2000)
out of THE in Korea and they have rapidly decreased due
to the expansion of health care insurance and other
factors. CONCLUSIONS: This shows that the OOP rate
in Korea is not severe as worried. Rather, high rates 
of prepaid could spend more in THE. We also argue 
that adequate levels of OOP rates in health insurance
systems could prevent unnecessary use of medical 
services, which follow to cost containment in THE.
However, this could be a barrier to accessing medical care
services for people on low incomes. Further studies on the
trade-offs between the levels of “barriers” and “moral
hazard” are suggested.
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OBJECTIVE: There is increasing concern that children
with special health care needs may face restricted access
to care due to potentially inadequate reimbursement to
health plans and providers caring for them. We employed
data from a State’s Medicaid, Title V and Title XXI pro-
grams to analyze the implications of different reimburse-
ment strategies. METHODS: Enrollment and claims data
for 188,556 children with at least 6 (aged 1–19) or 3
(newborns) months continuous enrollment during 1999
were employed. Children were grouped into mutually
exclusive Clinical Risk Group (CRG) categories (such as
healthy, malignancies and catastrophic). Reimbursement
models considered include demographics-adjusted capita-
tion, health-status adjusted capitation, carve-outs and
reinsurance for children with annual charges above a
threshold. RESULTS: Premium estimates from demo-
graphics-adjusted capitation model showed little varia-
tion across CRG categories within each program ($133
PMPM for healthy and $170 PMPM for moderate/dom-
inant chronic in the Title XXI program) resulting in
proﬁts on healthy ($42 PMPM) and losses on chronic
CRG categories (for example a loss of $191 PMPM for
minor chronic). While results from health-status adjusted
capitation model indicated wide disparity in premium
estimates across CRG categories ($94 PMPM for healthy
and $695 PMPM for moderate/dominant chronic in 
the Title XXI program), there still was wide variation in
expenditures within each CRG category creating incen-
tives to risk select. Financial risks to health plans and
providers were reduced slightly in malignancies and 
catastrophic carved-out model. More pronounced reduc-
tions in ﬁnancial risk were provided by reinsurance.
CONCLUSIONS: This study shows that demographics-
adjusted capitation fails to account for diverse ﬁnancial
needs of children with chronic conditions. Health-status
adjusted capitation, on average, supports varying needs
of children with chronic conditions, but the likelihood of
risk selection remains. Reinsurance further reduces incen-
tives to risk select, but incentives to control health care
costs are lost once charges exceed the threshold.
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OBJECTIVE: State funded healthcare systems, such as
the UK, tend to be cautious with the diffusion of new
drugs for fear of ﬁnancial pressures. One way of con-
trolling diffusion, while maximising the beneﬁts for
patients, is to set up an outcome guarantee. This presen-
tation describes a case study using lipid lowering drugs,
recently completed. METHODS: The key stakeholders
were identiﬁed and each declared their interest on an
agreed matrix. This formed the basis of an outcome guar-
antee contract. Near patient testing and audit nurses were
used to identify at risk patients and enter them into an
agreed care pathway. Patients were given lifestyle advice,
re-tested and monitored every 3 months throughout the
18 months of the project. Results of treatment with lipid
lowering drugs were measured against their claimed 
beneﬁts and adjusted for concordance. If the drug under-
performed, according to agreed criteria, the pharmaceu-
tical company agreed to refund the cost of those drugs.
RESULTS: The concept was readily accepted by the
stakeholders. Two thousand at risk patients were identi-
ﬁed from 1 primary care trust, of which 1400 were eligi-
ble to enter the outcome guarantee. Six hundred patients
to date have completed the project. Final results are due
in July. Of those who have completed the project, the
majority have reached target level and no refund has been
due. A qualitative evaluation of the stakeholders is cur-
rently under way and will be reporting in August 2002.
